Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bill would tweak DME competitive bidding

This article was originally published in The Gray Sheet

Executive Summary

Bill filed by Michigan Democratic Rep. John Dingell would help preserve in-house durable medical equipment services already offered by hospitals by allowing them to be compensated, whether or not they submitted a bid or were awarded a DME contract, at the rate determined by the Medicare competitive bidding process. The bill (H.R. 6095), which was introduced Aug. 10, was discussed by Dingell and others during a Sept. 15 hearing on DME competitive bidding by the House Committee on Energy and Commerce Subcommittee on Health. Dingell, who is chairman emeritus of the committee, has already received early support for the bill from organizations including the American Hospital Association. The hearing focused on the conception and implementation of the competitive bidding program, the implementation of the Round 1 re-bid and its potential effects on patients, providers and suppliers. Some legislators were encouraged by CMS testimony on how it has revised the program, but others continue to advocate ending competitive bidding in its current form, saying it will encourage systemic abuses, kill smaller DME distributors and hurt patient care. Home health care and medical product groups are among those who have been wary of the program 1("The Gray Sheet" July 12, 2010)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel